Google Cloud Expands Its Partnership With Ginkgo Bioworks For Two New AI-Tools Faster Drug Development
Google Cloud Expands Its Partnership With Ginkgo Bioworks For Two New AI-Tools Faster Drug Development
Tuesday, Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) announced two tools to streamline the drug development process for pharmaceutical and biotech companies.
星期二，庚果生物工程控股公司（紐交所: DNA）宣佈推出兩款工具，以簡化製藥和生物技術公司的藥物開發流程。
Building on its partnership with Alphabet Inc's (NASDAQ:GOOG) (NASDAQ:GOOGL) Google Cloud, Ginkgo introduced a protein large language model (LLM) and a model API, both designed to accelerate medicine development by leveraging AI and proprietary biological data.
庚果基於與Alphabet Inc（納斯達克：GOOG）（納斯達克：GOOGL）谷歌雲的合作，推出了一種蛋白質大型語言模型（LLM）和一個模型API，旨在通過利用人工智能和專有生物數據來加速藥物開發。
These offerings aim to simplify and enhance how researchers and companies discover new therapeutics.
這些產品旨在簡化和增強研究人員和公司發現新療法的過程。
Researchers at Google DeepMind have developed AlphaFold 3, an new artificial intelligence (AI) model.
Google DeepMind的研究人員開發了AlphaFold 3，一種新的人工智能（AI）模型。
AlphaFold 3 can predict the structure and interactions of biological molecules. This includes proteins, DNA RNA, and small molecules that could function as drugs.
AlphaFold 3可以預測生物分子的結構和相互作用。這包括蛋白質、DNA、RNA和可能作爲藥物的小分子。
The new protein LLM, developed in collaboration with Google Cloud Consulting and built on Vertex AI, offers powerful insights derived from Ginkgo's private data to individual researchers and enterprise companies.
庚果與谷歌雲諮詢合作並基於Vertex AI構建的新蛋白質LLm，爲個體研究人員和企業公司提供從庚果的專有數據中獲得的強大洞察力。
The model can help identify new therapeutic targets by analyzing protein structures and interactions, speeding up the discovery and development of life-saving medicines.
該模型可以通過分析蛋白質的結構和相互作用來幫助發現新的治療靶點，加快發現和開發拯救生命的藥物。
This tool is expected to revolutionize drug development pipelines, optimizing the process from lead identification to final approval.
預計這個工具將改變藥物開發流程，優化從引物識別到最終批准的過程。
In addition to the LLM, Ginkgo has launched its model API, an accessible and affordable tool aimed at providing machine learning scientists with AI models trained on Ginkgo's proprietary protein and DNA datasets.
除了LLm外，Ginkgo推出了其模型API，這是一個可訪問且價格實惠的工具，旨在爲機器學習科學家提供在Ginkgo的專有蛋白質和DNA數據集上訓練的AI模型。
This API is available on Ginkgo's website, with plans for enterprise access through Google Cloud's Vertex AI Model Garden.
此API可在Ginkgo的網站上獲得，計劃通過Google Cloud的Vertex AI模型中心提供企業訪問。
The API enables users to generate insights through advanced methods like masked language modeling and embedding calculations.
該API使用戶能夠通過像屏蔽語言建模和嵌入式計算這樣的先進方法生成見解。
Ankit Gupta highlighted that predictions on protein sequences could be obtained for as little as $0.18 per million tokens, allowing researchers to scale their experiments without incurring high costs.
Ankit Gupta強調，可以以每百萬個標記低至0.18美元的價格獲得對蛋白質序列的預測，這使研究人員能夠擴大其實驗範圍而不產生高昂的成本。
Ginkgo plans to release more models over the next year, broadening the API's capabilities and expanding its suite of tools to tackle complex drug discovery, synthetic biology, and genomics challenges.
Ginkgo計劃在未來一年推出更多模型，擴展API的功能，並擴大其一套工具以應對複雜的藥物發現、合成生物學和基因組學挑戰。
Price Action: DNA stock is up 11.60% at $6.95 at the last check on Tuesday.
股價走勢：截至週二最後一次檢查，DNA股價上漲11.60%，報6.95美元。
- Amazon's Leaner Structure and AI Chip Partnership with Intel Could Boost Growth: BofA Analyst.
- 亞馬遜精簡結構並與英特爾合作推出AI芯片，可能提振增長：美國銀行分析師。
Photo via Shutterstock
圖片來自shutterstock。